Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill'...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus n...
Aesculap, Inc., a leader in surgical innovation, announced the launch of its new Irrigating Specialty Non-Stick Disposable Bipolar Forceps to the U.S. ma...
Dedicated facilities for gelatin and HPMC; 200+ jobs; operations targeted for early 2027; expands ACG's 25-year U.S. presence ACG, the world's most inte...
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $10...
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rar...
Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...
-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s p...
Acquisition aims to strengthen company’s downstream process offering of advanced filtration and chromatography solutions JSR’s innovativ...
SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis...
-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective, announced the clea...
Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, announced the...
Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundat...
© 2025 Biopharma Boardroom. All Rights Reserved.
